Thursday, October 15, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· April 2, 2026

Nobody Could Answer the CFO’s Question on the ROI from AI Adoption; TechWish Built a Platform That Can

View original at finance.yahoo.com
Nobody Could Answer the CFO’s Question on the ROI from AI Adoption; TechWish Built a Platform That Can Platform validated at a major Fortune 500 energy company, establishing an estimated 20× productivity ROI and 44% increase in active Copilot utilization within 90 days STERLING, Va., April 02, 2026 (GLOBE NEWSWIRE) --…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • More than two-thirds of organizations continue to rely on manual or projected ROI tracking, even for AI systems already in production

    60% confidence
  • Native reporting dashboards inherent in AI tools can show baseline usage activity but lack contextual view required to answer leadership questions about genuine AI integration, enablement program effectiveness, and productivity outcomes

    60% confidence
  • More than two-thirds of organizations continue to rely on manual or projected ROI tracking for AI systems in production

    60% confidence
  • Only 39% of organizations report measurable business impact from generative AI, with two-thirds still characterizing their deployments as experimental or in piloting stages

    60% confidence
  • Evidence-based ROI reporting is becoming a board-level imperative, not just a reporting function

    60% confidence
  • Platform validated at a major Fortune 500 energy company, establishing an estimated 20× productivity ROI and 44% increase in active Copilot utilization within 90 days

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com